Duck IgY(ΔFc) Antibody Proprietary Technology Platform
Good Biotech Corp. is a fully integrated biotechnology company that develops, manufactures, and commercializes Duck IgY (ΔFc) antibodies from duck egg yolks for the uses of diagnostics and therapeutics. The company is the one and only manufacturer in the world which has had unprecedented success in building up the novel duck IgY(ΔFc) antibody technology platform. This proprietary technology has been validated through various products, such as IgY(ΔFc) antibody-based new generation immunoturbidimetric assay kits (with FDA 510(k) cleared), reagents for life science research, point of care products, and IgY(ΔFc) antibody-based biotherapeutics. Based upon the cutting-edge technology and the unique characteristics of duck IgY(ΔFc) antibody, Good Biotech has achieved promising results in the development of duck IgY(ΔFc) antibody derived Biotherapeutics, including but not limited to Snake Antivenom immunoglobulins, Digoxin Immune Fab (for the treatment of digoxin envenomation & severe preeclampsia), Neutralizing IgY(ΔFc) Antibodies to Multidrug-Resistant Bacterial Infections (e.g., pathogenic, Pseudomonas aeruginosa, Tuberculosis), anti-Obesity Nutraceutical, Food for Specific Health Use (FOCHU), and anti-Caries, Gastrointestinal Health Care Products. We primarily focus on the research and development efforts in the core application areas of the unique IgY(ΔFc) antibody listed below and are pursuing more products for these therapeutic areas.
Good Biotech is Committed to Addressing Unmet Global Medical Needs
Equine and ovine-based polyclonal antibodies are the major source of antivenoms, antitoxin (eg. anti-Rabies Immunoglobulins), and antidotes (e.g. digoxin antidote) at present. However, both equine/ovine-based biologicals suffer from lower efficacy, low productivity, high production costs, and the potential of life-threatening allergic reactions and/or biohazard risk. Therefore, many equine/ovine-based biologicals are still in shortage, such as Snake Antivenom Immunoglobulins, Digoxin Immune Fab, and with an urgent need. Unlike classical equine/ovine-based biologicals, production IgY (△Fc) antibody-based biotherapeutics in hyperimmune duck eggs possesses advantages including higher neutralizing activity, excellent productivity, lower production cost, simpler downstream processing, fast and large-scale production, and free from allergenicity/ biohazard risk of TSE. Production of duck IgY(ΔFc) antibodies is cost-effective, conforming to the expectation of animal protection organizations; and is timely in view of the World Health Organization’s (WHO) current initiative to review the quality, efficacy, safety, and affordable therapeutic antibodies. Thus, it is expected that IgY(ΔFc) derived next-generation Biotherapeutics will play a pivotal role and contribute to the popularity of specialty biopharmaceuticals that address high unmet medical needs.
Good Biotech Corp (GBC)’s novel duck IgY(ΔFc) antibody platform is a commercialized & validated technology (with a series of FDA 510(k) cleared clinical diagnostic products) that provides innovative solutions and a wide range of applications & possibilities. Good Biotech concentrates on developing innovative IgY(ΔFc) antibody-derived Biotherapeutics as acute/critical care specialty pharmaceutical products that address serious diseases in the areas of significant unmet health needs. The groundbreaking technology provides superior & alternative solutions to traditional methods in the market, and currently, available partnering opportunities include: (Click on each product for more information.)
IgY(ΔFc) antibody-derived Anti-Botulism Immunoglobulins
Neutralizing IgY(ΔFc) antibody against S.Mutans for anti-caries
Are you a potential partner?
Good Biotech's unique technology provides innovative & superior solutions to unmet global health needs. We are currently seeking Strategic Partnerships with leading global pharmaceutical companies who wish to access our experience and insights, as well as access our core competencies and with a proven track record in clinical experience, for completion of the final phases of the clinical trials, and commercial capabilities, to successfully bring our innovative developments to market. That ultimately fulfill the vision of the company "using duck IgY(ΔFc) antibody to improve the quality of life".
If you are interested in exploring a potential partnership, please contact Business Development at firstname.lastname@example.org